Document Detail


Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome.
MedLine Citation:
PMID:  18031326     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Prader-Willi syndrome (PWS) is a neurogenetic disorder characterized by muscular hypotonia, psychomotor delay, feeding difficulties and failure to thrive in infancy. GH treatment improves growth velocity and body composition. Research on the effects of GH on psychomotor development in infants with PWS is limited. OBJECTIVE: To evaluate psychomotor development in PWS infants and toddlers during GH treatment compared to randomized controls. DESIGN/PATIENTS: Forty-three PWS infants were evaluated at baseline. Twenty-nine of them were randomized into a GH group (n = 15) receiving 1 mg/m(2)/day GH or a non-GH-treated control group (n = 14). At baseline and after 12 months of follow-up, analysis with Bayley Scales of Infant Development II (BSID-II) was performed. Data were converted to percentage of expected development for age (%ed), and changes during follow-up were calculated. RESULTS: Infants in the GH group had a median age of 2.3 years [interquartile range (IQR) 1.7-3.0] and in the control group of 1.5 years (IQR 1.2-2.7) (P = 0.17). Both mental and motor development improved significantly during the first year of study in the GH group vs. the control group: median (IQR) change was +9.3% (-5.3 to 13.3) vs.-2.9% (-8.1 to 4.9) (P < 0.05) in mental development and +11.2% (-4.9 to 22.5) vs.-18.5% (-27.9 to 1.8) (P < 0.05) in motor development, respectively. CONCLUSION: One year of GH treatment significantly improved mental and motor development in PWS infants compared to randomized controls.
Authors:
D A M Festen; M Wevers; A C Lindgren; B Böhm; B J Otten; J M Wit; H J Duivenvoorden; A C S Hokken-Koelega
Related Documents :
23536976 - Virologic, immunologic and clinical response of infants to antiretroviral therapy in ka...
16675436 - Effects of prenatal exposure to polychlorinated biphenyls and dioxins on mental and mot...
24534016 - Successful caspofungin treatment of persistent candidemia in extreme prematurity at 23 ...
2438636 - Mental and motor development correlates in patients with end-stage biliary atresia awai...
12780366 - Maternal drug use and length of neonatal unit stay.
2240466 - Brain and liver pathology in a patient with carnitine deficiency.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2007-11-19
Journal Detail:
Title:  Clinical endocrinology     Volume:  68     ISSN:  1365-2265     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-05-20     Completed Date:  2009-07-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  919-25     Citation Subset:  IM    
Affiliation:
Dutch Growth Foundation, Rotterdam, The Netherlands. d.festen@erasmusmc.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Body Composition / drug effects
Child, Preschool
Female
Growth Hormone / therapeutic use*
Humans
Infant
Male
Prader-Willi Syndrome / drug therapy*
Psychomotor Disorders / drug therapy
Chemical
Reg. No./Substance:
9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Preclinical cardiac involvement in phaeochromocytoma: a study with integrated backscatter.
Next Document:  Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver dis...